Results 151 to 160 of about 119,522 (251)

Targeted Therapies for Each Subtype of Breast Cancer

MedComm, Volume 7, Issue 4, April 2026.
This review systematically summarizes the advances in targeted therapies for the three major molecular subtypes of breast cancer (BC), highlighting key strategies, agents, and clinical progress to guide personalized treatment. HR‐positive (luminal) BC: Dominated by estrogen receptor (ER) signaling, with endocrine therapies as the cornerstone—including ...
Aiyu Liu, Puchao Peng, Yeke Zhu, Qiuwen Fei, Weiwei Liu, Shizhen Zhang   +5 more
wiley   +1 more source

Protective Role for Itaconate During Inhaled Allergen Challenge

Allergy, Volume 81, Issue 4, Page 1099-1110, April 2026.
Itaconate levels decrease in sputum following allergen inhalation in mild asthmatics, suggesting a dynamic metabolic response to airway challenge. Genetic deletion of Acod1 in mice did not alter airway inflammation or remodelling in response to chronic HDM exposure.
Gesa J. Albers, Patricia P. Ogger, Christina Michalaki, Helen Stölting, Simone A. Walker, Anna Caldwell, John M. Halket, Kathryn Duvall, Atia Batool, Lisha Joshi, Helen O'Brien, Cormac McCarthy, Timothy Hinks, Gail M. Gauvreau, Paul M. O'Byrne, Clare M. Lloyd, Adam J. Byrne   +16 more
wiley   +1 more source

PFAPA syndrome study at Imam Khomeini Hospital Pediatrics Rheumatology Clinic in Ardabil from 2003 to 2007 [PDF]

Introduction: PFAPA(periodic fever, aphthous stomatitis, pharyngities, adenitis) syndrome is a new syndrome of periodic fevers that has been introduced in the past two decades.
جستان, مارینا, حبیب زاده, شهرام, دهقانزاده, رقیه, صالح زاده, فرهاد   +3 more
core  

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B‐Cell Non‐Hodgkin Lymphoma: Results From the Phase 1b J‐MIND Study

Cancer Science, Volume 117, Issue 4, Page 1093-1105, April 2026.
J‐MIND evaluated the safety and tolerability of tafasitamab, a CD19‐targeting monoclonal antibody, alone or in combination with other therapies in Japanese patients with B‐cell non‐Hodgkin lymphoma (NHL). Most common treatment‐emergent adverse events across all groups were hematological, and no serious tafasitamab treatment‐related or fatal adverse ...
Koji Izutsu, Noriko Fukuhara, Junichiro Yuda, Youko Suehiro, Shigeru Kusumoto, Marie‐Laure Casadebaig, Kazumi Suzukawa, Kentaro Fukushima   +7 more
wiley   +1 more source

Editorial: Methods in experimental pharmacology 2023

Frontiers in Pharmacology
Somasundaram Arumugam, Amit Khurana, Kala Kumar Bharani   +2 more
doaj   +1 more source

Pembrolizumab for Early‐Stage Triple‐Negative Breast Cancer: KEYNOTE‐522 Japan Subgroup Analysis

Cancer Science, Volume 117, Issue 4, Page 1106-1116, April 2026.
In the global, phase 3 KEYNOTE‐522 study of high‐risk early‐stage triple‐negative breast cancer (TNBC), neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab improved efficacy outcomes versus neoadjuvant chemotherapy alone. In this analysis of Japanese participants from KEYNOTE‐522, neoadjuvant pembrolizumab plus chemotherapy ...
Masato Takahashi, Hirofumi Mukai, Toshimi Takano, Koichiro Tsugawa, Kenichi Inoue, Mitsuya Itoh, Junichiro Watanabe, Yuko Tanabe, Naohito Yamamoto, Yasuo Miyoshi, Kenichi Watanabe, Toru Mukohara, Yibin Kong, Masashi Shimura, Francisco Beca, Peter Schmid, Hiroji Iwata   +16 more
wiley   +1 more source

Effects of glycyrrhizin on healing and prevention of recurrent aphthous stomatitis in hamster models. [PDF]

PLoS One
Shiba F, Maekawara S, Furusho H, Ishida E, Shigeishi H, Ohta K, Miyauchi M.   +6 more
europepmc   +1 more source

Impact of Sequential Ramucirumab Plus Docetaxel After PD‐1 Inhibitors on Anti‐PD‐1 Antibody‐Bound T‐Cell Dynamics and Clinical Outcomes

Cancer Science, Volume 117, Issue 4, Page 929-942, April 2026.
Ramucirumab (RAM) plus docetaxel (DOC) after PD‐1 inhibitors showed clinical activity, with responders exhibiting maintained anti–PD‐1 (IgG4+)‐bound CD8+ T cells and decreased IgG4+ Tregs. A sequential strategy of administering RAM plus DOC during persistent anti–PD‐1 antibody binding may be beneficial in patients with advanced non‐small cell lung ...
Kinnosuke Matsumoto, Yujiro Naito, Takayuki Shiroyama, Motohiro Tamiya, Kazumi Nishino, Akihiro Tamiya, Kyoichi Okishio, Yuhei Kinehara, Tomoki Kuge, Masahide Mori, Shingo Satoh, Hidekazu Suzuki, Satoshi Tetsumoto, Toshie Niki, Yasuhiko Suga, Akio Osa, Toshiyuki Minami, Shohei Koyama, Yoshito Takeda, Nobuyuki Takakura, Atsushi Kumanogoh   +20 more
wiley   +1 more source

Developing a Measure to Assess General Knowledge for Coeliac Disease

Health Expectations, Volume 29, Issue 2, April 2026.
ABSTRACT Background The importance of establishing knowledge about coeliac disease relates to the increasing incidence of symptomatic individuals who are undiagnosed. Objectives This study aimed to develop and pilot a tool that could be used to measure general knowledge regarding coeliac disease.
Tiffany Lavis, K. Ann Horsburgh, Jacqueline F. Gould, Elizabeth Bingham Thomas   +3 more
wiley   +1 more source

Development and Qualification of a Pseudotyped Virus‐Based Microneutralisation Assay for Influenza D Virus

Influenza and Other Respiratory Viruses, Volume 20, Issue 4, April 2026.
ABSTRACT Background Epidemiological surveillance of influenza D virus (IDV) has gained increased priority following recent serological findings indicating its potential zoonosis in humans. In this context, it is crucial to develop strong, reproducible, reliable and scalable immunological assays that can be quickly implemented in the surveillance of new
Maria Giovanna Marotta, Tobias Mapulanga, Meshach Maina, Janet Daly, Michele Camero, Pauline Mvan Diemen, Helen E. Everett, Emanuele Montomoli, Kelly da Costa, Nigel Temperton, Claudia Maria Trombetta   +10 more
wiley   +1 more source